PFE · Pfizer Inc.

Healthcare NYQ United States pfizer.com ↗
Val Gro Qua Mom Sta Cap P/S2.48 P/E Fwd P/E9.57 PEG2.72 52W –  RSI Target$28.88 (+4.2%) Beta0.30 Div6.22%
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Drug Manufacturers - General New York, United States 75,000 employees
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 53 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
4Bullish
4Bearish
0Neutral

Key Signals 1

▼ Double Top Major reversal 2026-06-18 · $24.84
Two peaks ~$26.05 — bearish reversal confirmed
Learn more →

Momentum Signals 7

▲ MACD Bullish Crossover 2026-05-21 · $25.5
▲ MACD Bullish Crossover 2026-07-10 · $23.75
▲ Bull Flag 2026-08-05 · $25.64
▲ Bull Flag 2026-08-19 · $27.4

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Nov 03, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +4.2%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
10
16
2
BuyHoldSell
Price Target Range
$28.88 +4.2% upside
Low $25 High $35
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 74.72%Last 12 Months
Operating Margin 27.88%Last 12 Months
Return on Equity 5.01%Last 12 Months
Revenue Growth 2.60%Year over Year
Free Cash Flow 12.49BLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 74.25Most Recent Quarter
Current Ratio 1.27Most Recent Quarter
Cash 11.70BMost Recent Quarter
Total Debt 63.48BMost Recent Quarter
Net Debt Most Recent Quarter
How PFE Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap157.99B
Enterprise Value210.07B
Trailing P/E36.47
Forward P/E9.57
PEG Ratio (5yr)2.72
Price/Sales (ttm)2.48
Price/Book (mrq)1.85
EV/Revenue3.30
EV/EBITDA8.28
Share Statistics
Avg Vol (3m)41.98M
Shares Outstanding5.70B
Float5.69B
% Held by Insiders0.10%
% Held by Institutions69.12%
Short Ratio3.91
Short % of Float2.66%
Profitability
Gross Margin74.72%
Operating Margin (ttm)27.88%
Profit Margin6.80%
Return on Assets (ttm)5.78%
Return on Equity (ttm)5.01%
Income Statement
Revenue (ttm)63.70B
Revenue Growth (yoy)2.60%
Gross Profit (ttm)47.59B
EBITDA25.38B
Net Income (ttm)4.34B
Diluted EPS (ttm)0.76
EPS Growth (yoy)N/A
Balance Sheet
Total Cash (mrq)11.70B
Total Debt (mrq)63.48B
Debt / Equity (mrq)74.25
Current Ratio (mrq)1.27
Book Value / Share14.95
Operating CF (ttm)13.40B
Free Cash Flow (ttm)12.49B
Trading & Dividends
Beta (5Y)0.30
50-Day MA26.19
200-Day MA26.21
Fwd Dividend Yield6.22%
Payout Ratio226.32%
Income
Dividend Yield 6.22%Last 12 Months
Annual Rate 1.72Forward
Payout Ratio 226.32%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 226.32%
Monthly Dividends
Ownership Breakdown
Institutional 69.12% Insider 0.10% Public 30.8%
Short Interest 2.66% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in PFE in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value